[Special Stock] IntronBio Highlights Joint Development of mRNA COVID-19 Vaccine Platform with Ilyeon Pharm

[Asia Economy Reporter Minwoo Lee] Intron Bio's stock price is on the rise. The news that it is jointly developing a messenger ribonucleic acid (mRNA) COVID-19 vaccine platform with Ilyang Pharmaceutical appears to have attracted attention.

At 10:07 a.m. on the 18th, Intron Bio's stock price recorded 26,750 KRW, up 8.30% from the previous day. The fact that it signed a vaccine platform joint development agreement with Ilyang Pharmaceutical, which is also capable of mRNA finished product manufacturing, seems to have acted as a positive factor. This is interpreted as increasing expectations for the development of an mRNA COVID-19 vaccine.

Earlier, at the end of last year, Intron Bio signed a memorandum of understanding (MOU) with Ilyang Pharmaceutical for joint development and commercialization of a vaccine platform. The plan is to promote the development of COVID-19 treatment-related technologies by combining Intron Bio's phage display technology with Ilyang Pharmaceutical's gene therapy technology and production facilities. Phage display is a technology that utilizes bacteriophages in the vaccine field.

Meanwhile, Ilyang Pharmaceutical recently explained, "Currently, our company is the only one in Korea that can produce both raw materials and finished pharmaceuticals for gene therapy and cell therapy products, and our scale is the largest. Since mRNA finished product manufacturing is also possible, vaccine and therapeutic developers collaborate from the early stages."

This content was produced with the assistance of AI translation services.